By Anthony Shevlin

Merck KGaA (MRK.XE) said Thursday that Intermolecular Inc. (IMI) stockholders have approved the acquisition by the German company.

The transaction is expected to close in the second half, Merck said.

The pharmaceutical company agreed to acquire Intermolecular in May through a subsidiary for $1.20 per share in an all-cash transaction, which represented an equity value of around $62 million.

Merck will acquire Intermolecular through its subsidiary EMD Group Holding II, Inc.

Write to Anthony Shevlin at anthony.shevlin@dowjones.com; @anthony_shevlin

(END) Dow Jones Newswires

July 18, 2019 04:25 ET (08:25 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Intermolecular (NASDAQ:IMI)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Intermolecular Charts.
Intermolecular (NASDAQ:IMI)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Intermolecular Charts.